Saquayamycin, with the CAS number 99260-65-8, is a natural product that belongs to the class of compounds known as anthracyclines, which are primarily recognized for their use in cancer therapy. This compound exhibits a complex molecular structure characterized by multiple rings and functional groups that contribute to its biological activity. Saquayamycin is known for its potent antitumor properties, which are attributed to its ability to intercalate DNA, thereby disrupting the replication and transcription processes within cancer cells. Additionally, it may induce apoptosis, or programmed cell death, in malignant cells. The compound has been studied for its efficacy against various types of cancer, although its clinical use may be limited due to potential side effects and toxicity. As with many anthracyclines, the pharmacokinetics of saquayamycin involve metabolism and excretion pathways that are crucial for understanding its therapeutic window and safety profile. Further research continues to explore its mechanisms of action and potential applications in oncology.

Saquayamycin is an "aquayamycin-type" antibiotic isolated from Streptomyces nodosus.

saquayamycin

99260-65-8: Saquayamycin, with the CAS number 99260-65-8, is a natural product that belongs to the class of compounds known as anthracyclines, which are primarily recognized for their use in cancer therapy. This compound exhibits a complex molecular structure characterized by multiple rings and functional groups that contribute to its biological activity. Saquayamycin is known for its potent antitumor properties, which are attributed to its ability to intercalate DNA, thereby disrupting the replication and transcription processes within cancer cells. Additionally, it may induce apoptosis, or programmed cell death, in malignant cells. The compound has been studied for its efficacy against various types of cancer, although its clinical use may be limited due to potential side effects and toxicity. As with many anthracyclines, the pharmacokinetics of saquayamycin involve metabolism and excretion pathways that are crucial for understanding its therapeutic window and safety profile. Further research continues to explore its mechanisms of action and potential applications in oncology.

<p>Saquayamycin A exhibits antibacterial properties, although its effect on Gram-negative bacteria is relatively weak. It also demonstrates inhibitory activity against leukemia P388 cells and adriamycin-resistant P388 cells.</p>

CAS 99260-65-8

saquayamycin

Saquayamycin A

Ref: TM-TN10072